A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Brief description of study

In this study, participants with high risk non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette Guerin (BCG) therapy and who are considered ineligible for or have elected not to undergo radical cystectomy, will receive pembrolizumab therapy.


Clinical Study Identifier: s14-01913
ClinicalTrials.gov Identifier: NCT02625961


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.